A Phase 1 interventional study of LY2835219 in Neoplasm Metastasis and Lymphoma, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-08-24.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing abemaciclib in Neoplasm Metastasis — 3 open to participants now, 8 under way, 3 of them phase 3. abemaciclib · Neoplasm Metastasis.
Among the 15 studies testing abemaciclib in Neoplasm Metastasis, this one is the 15th largest by enrollment, is the only one that started in 2013, is one of 5 in phase 1, and was the 1st registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 888 are open to participants now.
Browse Neoplasm Metastasis studies →3 of the 15 studies testing abemaciclib in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+ · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–90 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 689 Neoplasm Metastasis studies recruiting now, 536 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2013; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 50 across 3,270 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 48 across the 15 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 15 have an industry lead sponsor. The 7 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
72 studies in Neoplasm Metastasis by Eli Lilly and Company: 7 open now, 16 under way, 7 of them phase 3. Of 54 finished, 37 (69%) have results posted.
Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 60th largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2013, is one of 43 in phase 1, and was the 37th registered.
Eli Lilly and Company’s Neoplasm Metastasis studies by the year they started, since 2002.
2 of the studies testing abemaciclib in Neoplasm Metastasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07441369Fudan UniversityAbemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer | 2027-04-30 |
| NCT05095207Icahn School of Medicine at Mount SinaiAbemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing abemaciclib in Neoplasm Metastasis, from their registry updates:
Among Eli Lilly and Company’s 72 in Neoplasm Metastasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
Drug: LY2835219
150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
Drug: LY2835219
200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
Drug: LY2835219
Administered orally
Also known as: abemaciclib
Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)
DLT is defined as an adverse event between Day -3 and Day 29 of Cycle 1 that is possibly related to the study drug and fulfills any one of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
Time frame: Cycle 1 = 32 days
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Abemaciclib
Maximum plasma concentration on Day -3 and Day 28 of Cycle 1.
Time frame: Cycle 1 Day -3: Predose, 1, 2, 4, 6, 8, 10, 24, 48 and 72 hours (hr) postdose; Cycle 1 Day 28: Predose, 1, 2, 4, 6, 8, 10 and 24 hr postdose (Cycle 1 = 32 days)
Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of Abemaciclib
AUC on Day -3 and Day 28 of Cycle 1 are AUC from time zero to infinity \[AUC(0-∞)\] and AUC during one dosing interval at steady state (AUCτ,ss), respectively.
Time frame: Cycle 1 Day -3: Predose, 1, 2, 4, 6, 8, 10, 24, 48 and 72 hr postdose; Cycle 1 Day 28: Predose, 1, 2, 4, 6, 8, 10 and 24 hr postdose (Cycle 1 = 32 days)
Percentage of Participants With a Tumor Response: Objective Response Rate (ORR)
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
Time frame: Baseline to Measured Progressive Disease (Up To 24 months)
Participants completed the trial if they received at least one dose of study drug and met discontinuation criteria.
| Milestone | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib |
|---|---|---|---|
| Started | 3 | 3 | 6 |
| Received at least one dose of study drug | 3 | 3 | 6 |
| Completed | 3 | 3 | 6 |
| Not completed | 0 | 0 | 0 |
DLT is defined as an adverse event between Day -3 and Day 29 of Cycle 1 that is possibly related to the study drug and fulfills any one of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.
| Participants | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib |
|---|---|---|---|
| Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT) | 0 | 0 | 1 |
Maximum plasma concentration on Day -3 and Day 28 of Cycle 1.
| nanogram per milliliter (ng/mL) | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib |
|---|---|---|---|
| Cycle 1 Day -3 | 127 ± 51 | 167 ± 40 | 214 ± 87 |
| Cycle 1 Day 28 | NA ± NA | NA ± NA | 298 ± 64 |
AUC on Day -3 and Day 28 of Cycle 1 are AUC from time zero to infinity \[AUC(0-∞)\] and AUC during one dosing interval at steady state (AUCτ,ss), respectively.
| Nanogram*hour/Millilitre (ng*hr/mL) | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib |
|---|---|---|---|
| AUC(0-∞) | NA ± NA | 4450 ± 39 | 5480 ± 95 |
| AUCτ,ss (n=2,2,5) | NA ± NA | NA ± NA | 3020 ± 73 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions.
| percentage of participants | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib |
|---|---|---|---|
| Percentage of Participants With a Tumor Response: Objective Response Rate (ORR) | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - 100 mg Abemaciclib | — | 0/3 (0%) | 3/3 (100%) |
| Cohort 2 - 150 mg Abemaciclib | — | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 3 - 200 mg Abemaciclib | — | 2/6 (33.3%) | 6/6 (100%) |
| Event | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib |
|---|---|---|---|
| Gastric fistulaGastrointestinal disorders | 0/3 | 1/3 | 0/6 |
| Biliary tract infectionInfections and infestations | 0/3 | 1/3 | 0/6 |
| Lung infectionInfections and infestations | 0/3 | 1/3 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/3 | 1/6 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 1/6 |
| Deep vein thrombosisVascular disorders | 0/3 | 0/3 | 1/6 |
| Event | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/3 | 2/3 | 6/6 |
| Blood creatinine increasedInvestigations | 2/3 | 2/3 | 5/6 |
| LeukopeniaBlood and lymphatic system disorders | 2/3 | 0/3 | 1/6 |
| NeutropeniaBlood and lymphatic system disorders | 2/3 | 1/3 | 2/6 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/3 | 1/3 | 0/6 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 4/6 |
| Aspartate aminotransferase increasedInvestigations | 0/3 | 2/3 | 1/6 |
| White blood cell count decreasedInvestigations | 0/3 | 1/3 | 4/6 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 1/3 | 3/6 |
| NauseaGastrointestinal disorders | 1/3 | 0/3 | 3/6 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib | Total |
|---|---|---|---|---|
| Mean | 61.3 ± 11.06 | 63.0 ± 1.00 | 56.0 ± 11.70 | 59.1 ± 9.77 |
| Sex: Female, Male(Participants) | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 5 | 7 |
| Male | 2 | 2 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 6 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1 - 100 mg Abemaciclib | Cohort 2 - 150 mg Abemaciclib | Cohort 3 - 200 mg Abemaciclib | Total |
|---|---|---|---|---|
| Japan | 3 | 3 | 6 | 12 |
Plan to share: No
Ran from Dec 2013 to primary completion in Apr 2015, 15 months.
Results were first posted in Aug 2020, 5 years 4 months after primary completion.
Of 286 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 15 months is below that.
Counting every sponsor, half of 496 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib